SCHEMBL6990139

SCHEMBL6990139

O=C(c1cc2ccccc2nc1O)N1CCCC1Cc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SCD5 Q86SK9 2/20 0.53
HCRTR1 O43613 7/20 0.50
HCRTR2 O43614 7/20 0.50
CYP3A4 P08684 3/20 0.50
GABRA1 P14867 1/20 0.45
GABRG2 P18507 1/20 0.45
GABRB3 P28472 1/20 0.45
GABRA3 P34903 1/20 0.45
GABRA2 P47869 1/20 0.45
GABRB2 P47870 1/20 0.45
ROCK2 O75116 1/20 0.45
CTSD P07339 1/20 0.44
FABP4 P15090 1/20 0.43
TACR1 P25103 2/20 0.43
TACR3 P29371 1/20 0.42
ABHD6 Q9BV23 5/20 0.42
DAGLA Q9Y4D2 5/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6987290 0.92 HCRTR1 (0.48) SCD5HCRTR1HCRTR2CYP3A4FABP4
SCHEMBL6987244 0.90 HCRTR1 (0.50) SCD5HCRTR1HCRTR2CYP3A4FABP4
SCHEMBL6987311 0.85 FABP4 (0.45) SCD5HCRTR1HCRTR2CYP3A4FABP4
SCHEMBL6989431 0.85 HCRTR2 (0.44) SCD5HCRTR1HCRTR2CYP3A4
SCHEMBL6989539 0.84 SCD5 (0.55) SCD5HCRTR1HCRTR2CYP3A4GABRA1
SCHEMBL2477683 0.81 ALDH1A1 (0.49)
SCHEMBL6989978 0.81 SCD5 (0.51) SCD5HCRTR1HCRTR2CYP3A4FABP4
SCHEMBL6987991 0.77 FABP4 (0.49) SCD5HCRTR1HCRTR2CYP3A4FABP4
SCHEMBL6987127 0.76 SCD5 (0.46) SCD5FABP4TACR1TACR3
SCHEMBL6989556 0.76 HCRTR1 (0.48) SCD5HCRTR1HCRTR2CYP3A4FABP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8889683-B2 Substituted quinoxalines as inhibitors of fatty acid binding protein MERCK SHARP & DOHME CORP. (US) 2014-11-18 US disclosed
US-8889683-B2 Substituted quinoxalines as inhibitors of fatty acid binding protein MERCK SHARP & DOHME CORP. (US) 2014-11-18 US disclosed
US-20120122837-A1 INHIBITORS OF FATTY ACID BINDING PROTEIN MERCK SHARP & DOHME LLC 2012-05-17 US disclosed
US-20120122837-A1 INHIBITORS OF FATTY ACID BINDING PROTEIN MERCK SHARP & DOHME LLC 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122837-A1 INHIBITORS OF FATTY ACID BINDING PROTEIN FABP4, FABP1, FABP3 SCD5 40/4885HCRTR1 4346/4885HCRTR2 3592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.